SCHEMBL22625482

SCHEMBL22625482

BC(B)(B)Nc1ncc2cc(Br)c(C(B)(B)B)nc2n1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22625609 0.85 KRAS (0.31) —
SCHEMBL22612825 0.73 ULK1 (0.34) —
SCHEMBL29699267 0.61 RAF1 (0.38) —
SCHEMBL22612761 0.58 RAF1 (0.34) —
SCHEMBL22612769 0.58 FGFR1 (0.32) —
SCHEMBL31390052 0.54 SMN1; SMN2 (0.40) —
SCHEMBL31344333 0.52 HASPIN (0.36) —
SCHEMBL22625552 0.51 SMN1; SMN2 (0.33) —
SCHEMBL21416833 0.50 KRAS (0.34) —
SCHEMBL16683500 0.48 MEN1 (0.35) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11667634-B2 Inhibitors of RAF kinases KINNATE BIOPHARMA INC. (US) 2023-06-06 — — US disclosed
US-20210246135-A1 INHIBITORS OF RAF KINASES Pierre Fabre Médicament (FR) 2021-08-12 — — US disclosed
US-10927111-B2 Inhibitors of RAF kinases KINNATE BIOPHARMA INC. (US) 2021-02-23 — — US disclosed
US-20200347052-A1 INHIBITORS OF RAF KINASES Pierre Fabre Médicament (FR) 2020-11-05 — — US disclosed
Send feedback